Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Identifying unmet needs in long-term stroke care using in-depth assessment and the Post-Stroke Checklist - The Managing Aftercare for Stroke (MAS-I) study.

Hotter B, Padberg I, Liebenau A, Knispel P, Heel S, Steube D, Wissel J, Wellwood I, Meisel A.

Eur Stroke J. 2018 Sep;3(3):237-245. doi: 10.1177/2396987318771174. Epub 2018 Apr 19.

2.

Botulinumtoxin for bladder disorders.

Schulte-Baukloh H, Bauer R, Jost W, Wissel J, van Ophoven A.

Fortschr Neurol Psychiatr. 2019 Feb;87(1):23-30. doi: 10.1055/a-0599-0697. Epub 2018 Dec 3. Review. German.

PMID:
30508871
3.

Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity.

Creamer M, Cloud G, Kossmehl P, Yochelson M, Francisco GE, Ward AB, Wissel J, Zampolini M, Abouihia A, Calabrese A, Saltuari L.

Stroke. 2018 Sep;49(9):2129-2137. doi: 10.1161/STROKEAHA.118.022255.

4.

Reassembling of Alkali-Treated Casein Micelles by Microbial Transglutaminase.

Duerasch A, Wissel J, Henle T.

J Agric Food Chem. 2018 Nov 7;66(44):11748-11756. doi: 10.1021/acs.jafc.8b04000. Epub 2018 Oct 25.

PMID:
30350984
5.

The Use of Rhythmic Auditory Stimulation to Optimize Treadmill Training for Stroke Patients: A Randomized Controlled Trial.

Mainka S, Wissel J, Völler H, Evers S.

Front Neurol. 2018 Sep 14;9:755. doi: 10.3389/fneur.2018.00755. eCollection 2018.

6.

Towards flexible and tailored botulinum neurotoxin dosing regimens for focal dystonia and spasticity - Insights from recent studies.

Wissel J.

Toxicon. 2018 Jun 1;147:100-106. doi: 10.1016/j.toxicon.2018.01.018. Epub 2018 Jan 31. Review.

7.

Intrathecal baclofen therapy versus conventional medical management for severe poststroke spasticity: results from a multicentre, randomised, controlled, open-label trial (SISTERS).

Creamer M, Cloud G, Kossmehl P, Yochelson M, Francisco GE, Ward AB, Wissel J, Zampolini M, Abouihia A, Berthuy N, Calabrese A, Loven M, Saltuari L.

J Neurol Neurosurg Psychiatry. 2018 Jun;89(6):642-650. doi: 10.1136/jnnp-2017-317021. Epub 2018 Jan 11.

8.

A comprehensive person-centered approach to adult spastic paresis: a consensus-based framework.

Turner-Stokes L, Ashford S, Esquenazi A, Wissel J, Ward AB, Francisco G, Lains J, Suputtitada A, Serrano S, Baguley IJ, Barnes M, Simpson DM.

Eur J Phys Rehabil Med. 2018 Aug;54(4):605-617. doi: 10.23736/S1973-9087.17.04808-0. Epub 2017 Dec 21. Review.

9.

Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The TOWER study.

Wissel J, Bensmail D, Ferreira JJ, Molteni F, Satkunam L, Moraleda S, Rekand T, McGuire J, Scheschonka A, Flatau-Baqué B, Simon O, Rochford ET, Dressler D, Simpson DM; TOWER study investigators.

Neurology. 2017 Apr 4;88(14):1321-1328. doi: 10.1212/WNL.0000000000003789. Epub 2017 Mar 10.

10.

Poster 371 Escalating Doses of IncobotulinumtoxinA (400-800U) Are Well Tolerated and Lead to Increasing Improvements in Disability Due to Multifocal Upper- and Lower-Limb Spasticity.

Wissel J, Bensmail D, McGuire JR, Rubin BS, Scheschonka A, Simon O, Simpson DM.

PM R. 2016 Sep;8(9S):S282. doi: 10.1016/j.pmrj.2016.07.298. Epub 2016 Sep 24. No abstract available.

PMID:
27673123
11.

Poster 370 An International, Observational Study of Botulinum Toxin Type A in Spasticity - SPAsticity in PractiCE (SPACE).

Wissel J, Harriss JP, Simon O, Sternberg K, Roche N, Cantú-Brito C, Khatkova SE, Säterö P.

PM R. 2016 Sep;8(9S):S281. doi: 10.1016/j.pmrj.2016.07.297. Epub 2016 Sep 24. No abstract available.

PMID:
27673121
12.

Poster 289 Patient Registry of Spasticity Care World Data Analysis Based on Physician Experience.

Esquenazi A, Lee S, Mayer NH, Brashear A, Francisco GE, Yablon EE, Garreta R, Wissel J, Molteni F.

PM R. 2016 Sep;8(9S):S254. doi: 10.1016/j.pmrj.2016.07.462. Epub 2016 Sep 24. No abstract available.

PMID:
27673047
13.

OnabotulinumtoxinA Improves Pain in Patients With Post-Stroke Spasticity: Findings From a Randomized, Double-Blind, Placebo-Controlled Trial.

Wissel J, Ganapathy V, Ward AB, Borg J, Ertzgaard P, Herrmann C, Haggstrom A, Sakel M, Ma J, Dimitrova R, Fulford-Smith A, Gillard P.

J Pain Symptom Manage. 2016 Jul;52(1):17-26. doi: 10.1016/j.jpainsymman.2016.01.007. Epub 2016 Mar 30.

14.

Dystonia and Paroxysmal Dyskinesias: Under-Recognized Movement Disorders in Domestic Animals? A Comparison with Human Dystonia/Paroxysmal Dyskinesias.

Richter A, Hamann M, Wissel J, Volk HA.

Front Vet Sci. 2015 Nov 30;2:65. doi: 10.3389/fvets.2015.00065. eCollection 2015. Review.

15.

Post-stroke spasticity: predictors of early development and considerations for therapeutic intervention.

Wissel J, Verrier M, Simpson DM, Charles D, Guinto P, Papapetropoulos S, Sunnerhagen KS.

PM R. 2015 Jan;7(1):60-7. doi: 10.1016/j.pmrj.2014.08.946. Epub 2014 Aug 27. Review.

PMID:
25171879
16.

Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys (patients and physicians).

Bensmail D, Hanschmann A, Wissel J.

J Med Econ. 2014 Sep;17(9):618-25. doi: 10.3111/13696998.2014.925462. Epub 2014 Jun 12.

PMID:
24841450
17.

Early botulinum toxin treatment for spastic pes equinovarus--a randomized double-blind placebo-controlled study.

Fietzek UM, Kossmehl P, Schelosky L, Ebersbach G, Wissel J.

Eur J Neurol. 2014 Aug;21(8):1089-1095. doi: 10.1111/ene.12381. Epub 2014 Feb 12.

PMID:
24754350
18.

Functional goal achievement in post-stroke spasticity patients: the BOTOX® Economic Spasticity Trial (BEST).

Ward AB, Wissel J, Borg J, Ertzgaard P, Herrmann C, Kulkarni J, Lindgren K, Reuter I, Sakel M, Säterö P, Sharma S, Wein T, Wright N, Fulford-Smith A; BEST Study Group.

J Rehabil Med. 2014 Jun;46(6):504-13. doi: 10.2340/16501977-1817.

19.

Spasticity treatment with onabotulinumtoxin A: data from a prospective German real-life patient registry.

Schramm A, Ndayisaba JP, Auf dem Brinke M, Hecht M, Herrmann C, Huber M, Lobsien E, Mehnert S, Reuter I, Stenner A, van der Ven C, Winterholler M, Kupsch A, Wissel J.

J Neural Transm (Vienna). 2014 May;121(5):521-30. doi: 10.1007/s00702-013-1145-3. Epub 2014 Jan 10.

PMID:
24407377
20.

Efficacy and safety of botulinum toxin type A (Dysport) for the treatment of post-stroke arm spasticity: results of the German-Austrian open-label post-marketing surveillance prospective study.

Jost WH, Hefter H, Reissig A, Kollewe K, Wissel J.

J Neurol Sci. 2014 Feb 15;337(1-2):86-90. doi: 10.1016/j.jns.2013.11.022. Epub 2013 Nov 22.

21.

Impact of physical exercise on reaction time in patients with Parkinson's disease-data from the Berlin BIG Study.

Ebersbach G, Ebersbach A, Gandor F, Wegner B, Wissel J, Kupsch A.

Arch Phys Med Rehabil. 2014 May;95(5):996-9. doi: 10.1016/j.apmr.2013.10.020. Epub 2013 Nov 11.

PMID:
24231400
22.

An open-label cohort study of the improvement of quality of life and pain in de novo cervical dystonia patients after injections with 500 U botulinum toxin A (Dysport).

Hefter H, Benecke R, Erbguth F, Jost W, Reichel G, Wissel J.

BMJ Open. 2013 Apr 18;3(4). pii: e001853. doi: 10.1136/bmjopen-2012-001853. Print 2013.

23.

Pathophysiology of spasticity in stroke.

Burke D, Wissel J, Donnan GA.

Neurology. 2013 Jan 15;80(3 Suppl 2):S20-6. doi: 10.1212/WNL.0b013e31827624a7. Review.

PMID:
23319482
24.

Toward an epidemiology of poststroke spasticity.

Wissel J, Manack A, Brainin M.

Neurology. 2013 Jan 15;80(3 Suppl 2):S13-9. doi: 10.1212/WNL.0b013e3182762448. Review.

PMID:
23319481
25.

Classification of posture in poststroke upper limb spasticity: a potential decision tool for botulinum toxin A treatment?

Hefter H, Jost WH, Reissig A, Zakine B, Bakheit AM, Wissel J.

Int J Rehabil Res. 2012 Sep;35(3):227-33. doi: 10.1097/MRR.0b013e328353e3d4.

PMID:
22555318
26.

[Botulinum toxin in clinical neurology].

Wissel J, Kempf F.

Fortschr Neurol Psychiatr. 2012 Mar;80(3):167-78; quiz 179. doi: 10.1055/s-0031-1299095. Epub 2012 Mar 9. Review. German. No abstract available.

PMID:
22407413
27.

Evidence-based quality indicators for stroke rehabilitation.

Grube MM, Dohle C, Djouchadar D, Rech P, Bienek K, Dietz-Fricke U, Jöbges M, Kohler M, Missala I, Schönherr B, Werner C, Zeytountchian H, Wissel J, Heuschmann PU.

Stroke. 2012 Jan;43(1):142-6. doi: 10.1161/STROKEAHA.111.627679. Epub 2011 Oct 20.

PMID:
22020037
28.

Navigating the poststroke continuum of care.

Wissel J, Olver J, Sunnerhagen KS.

J Stroke Cerebrovasc Dis. 2013 Jan;22(1):1-8. doi: 10.1016/j.jstrokecerebrovasdis.2011.05.021. Epub 2011 Jul 5. Review.

PMID:
21733720
29.

Poststroke chronic disease management: towards improved identification and interventions for poststroke spasticity-related complications.

Brainin M, Norrving B, Sunnerhagen KS, Goldstein LB, Cramer SC, Donnan GA, Duncan PW, Francisco G, Good D, Graham G, Kissela BM, Olver J, Ward A, Wissel J, Zorowitz R; International PSS Disability Study Group.

Int J Stroke. 2011 Feb;6(1):42-6. doi: 10.1111/j.1747-4949.2010.00539.x. Review.

PMID:
21205240
30.

Rationale and design of a multicentre, double-blind, prospective, randomized, European and Canadian study: evaluating patient outcomes and costs of managing adults with post-stroke focal spasticity.

Borg J, Ward AB, Wissel J, Kulkarni J, Sakel M, Ertzgaard P, Åkerlund P, Reuter I, Herrmann C, Satkunam L, Wein T, Girod I, Wright N; BEST Study Group.

J Rehabil Med. 2011 Jan;43(1):15-22. doi: 10.2340/16501977-0663.

31.

Practical considerations for goal attainment scaling during rehabilitation following acquired brain injury.

Ertzgaard P, Ward AB, Wissel J, Borg J.

J Rehabil Med. 2011 Jan;43(1):8-14. doi: 10.2340/16501977-0664.

32.

[Botulinum toxin in the treatment of adult spasticity. An interdisciplinary German 10-point consensus 2010].

Wissel J, auf dem Brinke M, Hecht M, Herrmann C, Huber M, Mehnert S, Reuter I, Schramm A, Stenner A, van der Ven C, Winterholler M, Kupsch A.

Nervenarzt. 2011 Apr;82(4):481-95. doi: 10.1007/s00115-010-3172-8. German.

PMID:
21079908
33.

Comparison of an intermittent high-intensity vs continuous low-intensity physiotherapy service over 12 months in community-dwelling people with stroke: a randomized trial.

Hesse S, Welz A, Werner C, Quentin B, Wissel J.

Clin Rehabil. 2011 Feb;25(2):146-56. doi: 10.1177/0269215510382148. Epub 2010 Oct 4.

PMID:
20921029
34.

Split-screen video demonstration of sonography-guided muscle identification and injection of botulinum toxin.

Fietzek UM, Schroeder AS, Wissel J, Heinen F, Berweck S.

Mov Disord. 2010 Oct 15;25(13):2225-8. doi: 10.1002/mds.23113.

PMID:
20721881
35.

Occurence and clinical predictors of spasticity after ischemic stroke.

Urban PP, Wolf T, Uebele M, Marx JJ, Vogt T, Stoeter P, Bauermann T, Weibrich C, Vucurevic GD, Schneider A, Wissel J.

Stroke. 2010 Sep;41(9):2016-20. doi: 10.1161/STROKEAHA.110.581991. Epub 2010 Aug 12.

PMID:
20705930
36.

Comparing exercise in Parkinson's disease--the Berlin LSVT®BIG study.

Ebersbach G, Ebersbach A, Edler D, Kaufhold O, Kusch M, Kupsch A, Wissel J.

Mov Disord. 2010 Sep 15;25(12):1902-8. doi: 10.1002/mds.23212. Erratum in: Mov Disord. 2010 Oct 30;25(14):2478.

PMID:
20669294
37.

The profile of patients and current practice of treatment of upper limb muscle spasticity with botulinum toxin type A: an international survey.

Bakheit AM, Zakine B, Maisonobe P, Aymard C, Fhedoroff K, Hefter H, Jacinto J, Jost WH, Molteni F, Stam H, Turner-Stokes L, Wissel J.

Int J Rehabil Res. 2010 Sep;33(3):199-204. doi: 10.1097/MRR.0b013e328332f5e0.

PMID:
20154631
38.

Early development of spasticity following stroke: a prospective, observational trial.

Wissel J, Schelosky LD, Scott J, Christe W, Faiss JH, Mueller J.

J Neurol. 2010 Jul;257(7):1067-72. doi: 10.1007/s00415-010-5463-1. Epub 2010 Feb 6.

39.

Case histories in pharmaceutical risk management.

McCormick CG, Henningfield JE, Haddox JD, Varughese S, Lindholm A, Rosen S, Wissel J, Waxman D, Carter LP, Seeger V, Johnson RE.

Drug Alcohol Depend. 2009 Dec 1;105 Suppl 1:S42-55. doi: 10.1016/j.drugalcdep.2009.08.003. Epub 2009 Sep 19.

PMID:
19767156
40.

Botulinum toxin B increases mouth opening in patients with spastic trismus.

Fietzek UM, Kossmehl P, Barthels A, Ebersbach G, Zynda B, Wissel J.

Eur J Neurol. 2009 Dec;16(12):1299-304. doi: 10.1111/j.1468-1331.2009.02723.x. Epub 2009 Jun 29.

PMID:
19566902
41.

Cost-effectiveness modeling of intrathecal baclofen therapy versus other interventions for disabling spasticity.

Bensmail D, Ward AB, Wissel J, Motta F, Saltuari L, Lissens J, Cros S, Beresniak A.

Neurorehabil Neural Repair. 2009 Jul-Aug;23(6):546-52. doi: 10.1177/1545968308328724. Epub 2009 Feb 19.

PMID:
19228818
42.

European consensus table on the use of botulinum toxin type A in adult spasticity.

Wissel J, Ward AB, Erztgaard P, Bensmail D, Hecht MJ, Lejeune TM, Schnider P, Altavista MC, Cavazza S, Deltombe T, Duarte E, Geurts AC, Gracies JM, Haboubi NH, Juan FJ, Kasch H, Kätterer C, Kirazli Y, Manganotti P, Parman Y, Paternostro-Sluga T, Petropoulou K, Prempeh R, Rousseaux M, Slawek J, Tieranta N.

J Rehabil Med. 2009 Jan;41(1):13-25. doi: 10.2340/16501977-0303.

43.

[Multidisciplinary therapy for focal spasticity treatment].

Wissel J.

Nervenarzt. 2008 Jun;79 Suppl 1:24-8. Review. German.

PMID:
18927962
44.

Whole body vibration versus conventional physiotherapy to improve balance and gait in Parkinson's disease.

Ebersbach G, Edler D, Kaufhold O, Wissel J.

Arch Phys Med Rehabil. 2008 Mar;89(3):399-403. doi: 10.1016/j.apmr.2007.09.031.

PMID:
18295614
45.

Botulinum neurotoxin type A injections reduce spasticity in mild to moderate hereditary spastic paraplegia--report of 19 cases.

Hecht MJ, Stolze H, Auf dem Brinke M, Giess R, Treig T, Winterholler M, Wissel J; German Spasticity Education Group.

Mov Disord. 2008 Jan 30;23(2):228-33.

PMID:
17999430
46.

Using translational medicine to understand clinical differences between botulinum toxin formulations.

Aoki KR, Ranoux D, Wissel J.

Eur J Neurol. 2006 Dec;13 Suppl 4:10-9. Review.

PMID:
17112345
47.

Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial.

Wissel J, Haydn T, Müller J, Brenneis C, Berger T, Poewe W, Schelosky LD.

J Neurol. 2006 Oct;253(10):1337-41. Epub 2006 Sep 20.

PMID:
16988792
48.

Treatment of adductor spasticity with BTX-A in children with CP: a randomized, double-blind, placebo-controlled study.

Mall V, Heinen F, Siebel A, Bertram C, Hafkemeyer U, Wissel J, Berweck S, Haverkamp F, Nass G, Döderlein L, Breitbach-Faller N, Schulte-Mattler W, Korinthenberg R.

Dev Med Child Neurol. 2006 Jan;48(1):10-3.

49.

Use of botulinum toxin type A in management of adult spasticity. A European consensus statement.

Ward AB, Aguilar M, De Beyl Z, Gedin S, Kanovsky P, Molteni F, Wissel J, Yakovleff A.

Eura Medicophys. 2004 Jun;40(2):83-4. No abstract available.

50.

The effect of nabilone on neuropsychological functions related to driving ability: an extended case series.

Kurzthaler I, Bodner T, Kemmler G, Entner T, Wissel J, Berger T, Fleischhacker WW.

Hum Psychopharmacol. 2005 Jun;20(4):291-3.

PMID:
15834843

Supplemental Content

Loading ...
Support Center